Sight sciences CEO Paul Badawi sells shares worth $55,672

Published 04/04/2025, 03:02
Sight sciences CEO Paul Badawi sells shares worth $55,672

Paul Badawi, the President and CEO of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 24,174 shares of the company’s common stock. The medical device company, currently valued at $116.5 million, has seen its stock decline over 61% in the past six months, according to InvestingPro data. The sale, conducted on April 1, 2025, was completed at an average price of $2.303 per share, totaling approximately $55,672. This transaction was made to cover tax liabilities related to the vesting of restricted stock units. Following the sale, Badawi retains ownership of 6,010,580 shares in the company, representing substantial insider ownership despite recent stock volatility. InvestingPro analysis reveals the company maintains a strong balance sheet with more cash than debt, though it’s currently trading below its Fair Value.

In other recent news, Sight Sciences Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company recorded an EPS of -$0.23, just below the anticipated -$0.22, and revenue of $19.1 million, falling short of the expected $20.26 million. The revenue shortfall was primarily attributed to challenges in the Surgical Glaucoma segment, exacerbated by Medicare Local Coverage Determinations (LCDs) changes. Despite these results, Sight Sciences’ surgical glaucoma revenue showed a robust 9% year-over-year growth, contributing to a 2% overall revenue increase compared to the previous year. Analysts from Stifel revised their price target for Sight Sciences, lowering it to $4.00 from $5.00, yet maintained a Buy rating, citing potential reimbursement for TearCare as a positive catalyst. The company provided guidance for 2025, projecting revenue between $70 million and $75 million, with expectations of initial reimbursement decisions for TearCare, which could positively impact future revenue streams. Sight Sciences remains focused on achieving cash flow breakeven without additional equity capital, supported by a strong balance sheet. The company anticipates that the impact of the LCD changes will be fully realized by the end of 2025, and it sees opportunities in the standalone MIGS market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.